Features of Study Participants.

<p>Definition of abbreviations: M, male; F, female; C, Caucasian; AA, African Amirican; FEV₁, Forced expiratory volume in 1 second; FVC, Forced vital capacity;</p><p><b>*</b><i>P</i> value, asthma <i>vs</i>. controls.</p><p>Features of Study Participants.</p

Greater TCA Cycle Activity in Asthma.

<p>(A) ATP content in control (white bars) and asthmatic (black bars) individuals basally and after inhibition of glycolysis by 2-DG. (B) Western analyses of aconitase expression in platelets. Asthmatic individials (lanes 4−6) had similar aconitase protein expression in platelets to healthy controls (lanes 1−3) by western blot. (C) Activity of aconitase, succinate dehydrogenase and citrate synthase in platelets from asthmatics (black bars) as a fold change of the activity of control platelets (white bars). n = 13 controls, n = 10 asthmatics. *p<0.01; #p<0.05.</p

Platelets show decreased glycolytic rate in asthma.

<p>(A) Extracellular acidification rate (ECAR) trace in asthmatic (filled squares) and healthy controls (open squares) basally, after the addition of oligomycin A, FCCP and 2-DG. (B) Quantification of ECAR basally, after oligomycin A addition and 2DG treatment in healthy controls (open bars) and asthmatic platelets (filled bars). (C-D) ECAR basally and after oligomycin A addition for platelets from each (C) healthy control subject and (D) asthmatic individuals. (E) Quantification of the difference in ECAR from basal to oligomycin A addition in healthy (control)(white bar) and asthmatic individuals (black bar). (F) The change in ECAR as a function of OCR in healthy (open circles) and asthmatic (filled squares) platelets basally and after the addition of oligomycin A. Arrows show the shift in ECAR/OCR after oligomycin A addition. n = 12 asthma, n = 13 controls; *p<0.01; #p<0.05.</p

The prevalence of asthma at our institution in all children and children with nephrolithiasis.

<p>The prevalence of asthma at our institution in all children and children with nephrolithiasis.</p

Platelets show less reliance on glycolysis in asthma.

<p>(A) Oxygen consumption trace for healthy (open squares) and asthmatic (filled squares). Basal rate is shown and arrows denote the addition of oligomycin A (oligo), FCCP, 2-deoxyglucose (2DG) and rotenone. (B) Quantification of basal rate, proton leak, ATP-linked respiration and non-mitochondrial oxygen consumption in platelets from healthy (open bars) and asthmatic (filled bars) subjects (calculated from traces such as those shown in panel A). (C) Quantification of oxygen consumption rate after the addition of 2-DG in healthy (open bars) and asthmatic (filled bars) platelets. (D) Changes in OCR as a function of ECAR in healthy (control; open circles) and asthmatic (Asthma; filled squares) platelets basally and after the addition of 2-DG. Arrows depict the shift after addition of 2-DG. Data are means ± SEM. #p<0.05. n = 12 for asthma, n = 13 for control.</p

Asthmatics show airflow obstruction compared to healthy controls.

<p>Airflow obstruction as measured by (A) FEV1% predicted and (B) FEV1/FVC in asthmatic individuals compared with healthy control subjects. #p<0.05.</p

Platelets show no change in mitochondrial number and morphology in asthma.

<p>(A-B) Representative electron micrograph of platelet from (A) healthy control and (B) asthma (scale bars: 1 μm). (C) Mitochondrial DNA copy number per platelet in platelets from healthy and asthmatic individuals. n = 7 per group.</p

Clinical-Demographic data for current pediatric patients stratified by asthma and kidney stone diagnosis.

<p>Clinical-Demographic data for current pediatric patients stratified by asthma and kidney stone diagnosis.</p

Prescribed asthma medication comparison between asthma patients with and without kidney stones matched by age gender and BMI.

<p>Prescribed asthma medication comparison between asthma patients with and without kidney stones matched by age gender and BMI.</p

Clinical-demographic data comparison between asthma-stone patients and stone patients without asthma.

<p>Clinical-demographic data comparison between asthma-stone patients and stone patients without asthma.</p